NCT00135356 - Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome | Biotech Hunter

Enrollment

219

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

June 30, 2008

Conditions

HIV-Associated Lipodystrophy Syndrome

Interventions

DRUG

Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)

Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks

DRUG

continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)

Protease inhibitor \[PI\] combination + 2 NRTIs

Trial Locations (30)

Unknown

Local Institution, Fort Lauderdale

Local Institution, Honolulu

Local Institution, Huntersville

Local Institution, Houston

Local Institution, Ottawa

Local Institution, Toronto

Local Institution, Bondy

Local Institution, Lagny-sur-Marne

Local Institution, Lyon

Local Institution, Nice

Local Institution, Paris

Local Institution, Frankfurt am Main

Local Institution, München

Local Institution, Brescia

Local Institution, Milan

Local Institution, Modena

Local Institution, Roma

Local Institution, Guadalajara

Local Institution, Zapopan

Local Institution, Puebla City

Local Institution, Szczecin

Local Institution, Wroclaw

Local Institution, Barcelona

Local Institution, Elche (Alicante)

Local Institution, Guipuzcoa

Local Institution, Madrid

Local Institution, Málaga

Local Institution, Valencia

Local Institution, Brighton

Local Institution, London